Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6357275 | 0.88 | EPHX2 (0.48) | ALDH1A1KMT2ASMN1; SMN2MAPTRAB9A | |
| SCHEMBL8700410 | 0.86 | ALDH1A1 (0.47) | ALDH1A1KMT2ASMN1; SMN2MAPTRAB9A | |
| SCHEMBL6357782 | 0.84 | NLRP3 (0.52) | ALDH1A1KMT2ASMN1; SMN2MAPTRAB9A | |
| SCHEMBL6355171 | 0.83 | SMN1; SMN2 (0.52) | ALDH1A1KMT2ASMN1; SMN2MAPTRAB9A | |
| SCHEMBL6355594 | 0.81 | PPARG (0.50) | ALDH1A1KMT2ASMN1; SMN2MAPTRAB9A | |
| SCHEMBL8409841 | 0.81 | SMN1; SMN2 (0.48) | ALDH1A1KMT2ASMN1; SMN2MAPTRAB9A | |
| SCHEMBL6357278 | 0.80 | EPHX2 (0.52) | ALDH1A1KMT2ASMN1; SMN2MAPTRAB9A | |
| SCHEMBL6359228 | 0.79 | PPARG (0.47) | ALDH1A1KMT2ASMN1; SMN2RAB9AMEN1 | |
| Efaproxiral SCHEMBL1649963 | 0.78 | PPARA (0.54) | ALDH1A1KMT2ASMN1; SMN2MAPTRAB9A | |
| SCHEMBL12998282 | 0.77 | MEN1 (0.53) | ALDH1A1KMT2ASMN1; SMN2MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170326086-A1 | USE OF HEMOGLOBIN EFFECTORS TO INCREASE THE BIOAVAILABILITY OF THERAPEUTIC GASES | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326086-A1 | USE OF HEMOGLOBIN EFFECTORS TO INCREASE THE BIOAVAILABILITY OF THERAPEUTIC GASES | HBG2, HBG1, HBB | ALDH1A1 4291/4885KMT2A 3386/4885SMN1; SMN2 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.